Murphy Canyon Acquisition called a Sept. 7 meeting at 10 a.m. Eastern for shareholders to vote on the proposed merger with Conduit Pharmaceuticals.
The transactions is expecgted to be completed by the end of the third quarter, with Conduit shares and warrants listing on the Nasdaq under the symbols CDT and CDTTW.
San Diego-based Conduit expects to use proceeds from the deal to accelerate development of its autoimmune disease and idiopathic male infertility pipeline.
The $700.5 million deal was announced in November. Cash proceeds are expected to consist of up to approximately $136.04 million held in Murphy’s trust account (before any redemptions and payment of expenses) and a $27 million PIPE. Read more.
